Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06400498 · ClinicalTrials.gov registry record · NA
Surprise Question in End of Life (SeQuEL) Care and the Effect of Prompting Palliative Care Consultation: End-Stage Liver Disease
A NA study of End Stage Liver DIsease, sponsored by Vanderbilt University Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 97
- Enrollment target
- 1
- Study location
NCT06400498: Completed NA study of End Stage Liver DIsease, sponsored by Vanderbilt University Medical Center.
NCT06400498 is a NA study of End Stage Liver DIsease that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 97 participants, below the 485-participant average among 16 other End Stage Liver DIsease trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06400498, a NA study of End Stage Liver DIsease, has completed, sponsored by Vanderbilt University Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 97 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single center randomized platform trial determining whether prompting consideration of palliative care consultation through the electronic health record impacts the number of palliative consultations placed and hospital-free days among hospitalized adults with End-Stage Liver Disease.
Primary Outcome
Percentage of patients identified within the EHR identified with palliative care consults.
Conditions Studied
Interventions
- BEHAVIORAL Prompted Palliative Care Consult
Study Locations (1)
Tennessee
- Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 97 participants |
| Start Date | 2024-08-05 |
| Est. Completion | 2025-08-05 |
| Phase | NA |
What the finished NCT06400498 record still lists
NCT06400498 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 97 participants, a relatively small participant target, below the 485-participant average among 16 other End Stage Liver DIsease trials with a reported enrollment target (80% lower).
The record links to 1 condition, with End Stage Liver DIsease appearing as the primary indexed condition, and to 1 intervention - of which Prompted Palliative Care Consult is the first listed.
NCT06400498 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT06400498 about?
NCT06400498 is a clinical study titled "Surprise Question in End of Life (SeQuEL) Care and the Effect of Prompting Palliative Care Consultation: End-Stage Liver Disease". This is a single center randomized platform trial determining whether prompting consideration of palliative care consultation through the electronic health record impacts the number of palliative consultations placed and hospital-free days among hospitalized adults with End-Stage Liver Disease.
What is the current status of trial NCT06400498?
This trial is currently completed. It is a NA study. The enrollment target is 97 participants. The study started on 2024-08-05. Estimated completion is 2025-08-05.
What conditions does trial NCT06400498 study?
This clinical trial studies the following conditions: End Stage Liver DIsease.
What interventions are being tested in trial NCT06400498?
The interventions under investigation include: Prompted Palliative Care Consult (BEHAVIORAL).
Who is sponsoring clinical trial NCT06400498?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06400498 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for End Stage Liver DIsease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06400498's enrollment target sits among peer trials
97 11th of 16 higher than 6 of 16 other End Stage Liver DIsease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other End Stage Liver DIsease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
HepHospital: A Pilot Trial of a Hepatology Home Hospital Intervention for Patients With Advanced Liver Disease
RECRUITING · NA
-
Adverse Outcomes and Mortality in Liver Transplant
RECRUITING · NA
-
LiverPAL: A Trial of Inpatient Palliative Care for Patients With Advanced Liver Disease
RECRUITING · NA
-
Testing LiverWatch, a Home-Based Remote-Monitoring Intervention for Advanced Liver Disease
RECRUITING · NA
-
Technology Enabled Strategies to Promote Treatment Adherence in Liver Transplant
RECRUITING · NA
-
Dissemination of the Donor Application: Utilizing Social Media to Identify Potential Live Organ Donors
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03948490 · 97 participants · NA
Rehabilitation and Longitudinal Follow-up of Cognition in Adult Lower Grade Gliomas
- NCT04140487 · 97 participants · Phase 1
Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm
- NCT04196413 · 97 participants · Phase 1
GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas (DIPG) & Spinal Diffuse Midline Glioma(DMG)
- NCT05223816 · 97 participants · Phase 2
An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI